Clinical trial · Observational
Impact of GLP-1 Receptor Agonists on Patients With IPMN
Impact of GLP-1 Receptor Agonists on Patients With Intraductal Papillary Mucinous Neoplasms: A Retrospective Multicentric Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy. With the increasing use of GLP-1 RAs for managing diabetes and obesity, concerns about their potential to influence pancreatic conditions, like IPMNs, have emerged. Although GLP-1 RAs are generally safe, their effects on pre-existing pancreatic conditions remain unclear. The study aims to evaluate whether GLP-1 RA use in IPMN patients is linked to changes in pancreatic cyst characteristics, the incidence of acute pancreatitis, variations in tumor markers, and the progression of IPMNs to high-grade dysplasia or malignancy. A retrospective analysis will be conducted using medical data from patients diagnosed with IPMNs and treated with GLP-1 RAs between 2010 and 2024 at three Swiss hospitals. Key outcomes will include radiological changes, the incidence of acute pancreatitis, and potential shifts in IPMN surveillance or need for surgical intervention
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| GLP-1 | — | UNRESOLVED | — |
| Glucagon-Like Peptide-1 Receptor Agonists | — | UNRESOLVED | — |
| Intraductal Papillary Mucinous Neoplasm of Pancreas | Pancreatic Intraductal Neoplasm | PROBABILISTIC | 0.70 |
| IPMN | — | UNRESOLVED | — |
| IPMN, Pancreatic | Pancreatic Intraductal Papillary Mucinous Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GLP1 receptor agonist | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Intraductal Papillary Mucinous Neoplasms
- description
- Patients eligible for this study must have a radiological diagnosis of IPMN
- interventionNames
- Drug: GLP1 receptor agonist
Primary outcomes (1)
- measure
- Radiological changes in pancreatic cyst characteristic as described in the Kyoto 2023 Consensus
- timeFrame
- during the GLP1 RA treatment
- description
- Radiological data, including data from MRI scans, will be used to monitor changes in IPMN characteristics. If only CT scans are available, they will also be evaluated, even if this is not the preferred imaging method for IPMN evaluation
Secondary outcomes (6)
- measure
- Incidence of acute pancreatitis
- timeFrame
- during the GLP1 RA treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \> 18 years old * Radiological diagnosis of IPMN * Treated with GLP-1 RAs. * Patients must have provided prior informed consent for the use of their coded clinical data in research. Exclusion Criteria: * radiological diagnosis of IPMN is unclear, * no documented history of GLP-1 RAs use * patients did not provide signed informed consent, or have documented refusal for research.
References
Publications (1)
- RESULTOhtsuka T, Fernandez-Del Castillo C, Furukawa T, Hijioka S, Jang JY, Lennon AM, Miyasaka Y, Ohno E, Salvia R, Wolfgang CL, Wood LD. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology. 2024 Mar;24(2):255-270. doi: 10.1016/j.pan.2023.12.009. Epub 2023 Dec 28. PMID 38182527